신경내분비종양 치료 시장 규모, 점유율, 성장 분석 : 종양 유형별, 치료 제품별, 부위별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Global Neuroendocrine Tumors Treatment Market size was valued at USD 2.48 Billion in 2024 and is poised to grow from USD 2.62 Billion in 2025 to USD 4.11 Billion by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).

The global prevalence of neuroendocrine tumors (NET), often arising from neurological and endocrine cells, is on the rise, with carcinoid tumors predominantly found in the gastrointestinal tract, as well as the appendix, rectum, pancreas, and lungs. These tumors may present as benign or malignant and can lead to various symptoms, including gastrointestinal issues, chronic coughing, and cardiovascular problems. The market for neuroendocrine tumor treatments is poised for substantial growth, driven by increased research and development investments, the introduction of innovative therapies, and advancements in diagnostic techniques that facilitate early detection. This combination of factors contributes to enhanced market dynamics and the proliferation of effective treatment options for patients globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neuroendocrine Tumors Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neuroendocrine Tumors Treatment Market Segments Analysis

Global Neuroendocrine Tumors Treatment Market is segmented by Tumor Types, Treatment Products, Sites, End Uses and region. Based on Tumor Types, the market is segmented into Meningiomas, Adrenal Cancer, Carcinoid Tumors, Paraganglioma, Pheochromocytoma and Others. Based on Treatment Products, the market is segmented into Somatostatin Analogs (SSAs), Targeted Therapy and Others. Based on Sites, the market is segmented into Lung, Pancreas, Colon, Small Intestine, Rectum, Stomach and Others. Based on End Uses, the market is segmented into Hospitals, Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is significantly influenced by the increasing incidence and prevalence of neuroendocrine tumors (NET) across the globe. As more individuals are diagnosed with this rare condition, there is a growing demand for effective treatment options. This heightened awareness and incidence drive the adoption of medications specifically designed for NET, contributing to market growth. The result is a rising urgency for innovative therapies and targeted treatments that cater to the needs of patients, ultimately shaping the landscape of the neuroendocrine tumors treatment market and fueling its advancement as healthcare providers seek to address this pressing medical challenge.

Restraints in the Global Neuroendocrine Tumors Treatment Market

The growth of the Global Neuroendocrine Tumors Treatment market is likely to face significant challenges due to the substantial costs associated with developing effective therapies and the potential side effects linked to these treatments. Patients undergoing treatment may experience various adverse effects, such as elevated blood sugar levels, gallstone formation, and gastrointestinal issues like bloating and nausea. These factors could deter both patients and healthcare providers from pursuing these therapies, thereby influencing market dynamics and limiting the overall expansion of the sector in response to unmet medical needs. Addressing these challenges will be crucial for future market development.

Market Trends of the Global Neuroendocrine Tumors Treatment Market

The Global Neuroendocrine Tumors Treatment market is experiencing significant growth, with somatostatin analogs (SSAs) emerging as the leading therapeutic option. These medications effectively manage tumor growth, alleviate symptoms, and serve as reliable biomarkers, making them preferred treatments for many patients. SSAs command a substantial revenue share in the market due to their safety and efficacy, particularly for those not suitable for radiotherapy or surgery. Additionally, the ongoing clinical trials and forthcoming approvals of novel SSA formulations promise to further enhance their market position, indicating a robust and dynamic landscape in neuroendocrine tumor therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Regulatory Analysis
• Patent Analysis
• Case Studies

Global Neuroendocrine Tumors Treatment Market Size by Tumor Types & CAGR (2026-2033)

• Market Overview
• Meningiomas
• Adrenal Cancer
• Carcinoid Tumors
• Paraganglioma
• Pheochromocytoma
• Others

Global Neuroendocrine Tumors Treatment Market Size by Treatment Products & CAGR (2026-2033)

• Market Overview
• Somatostatin Analogs (SSAs)
• Targeted Therapy
• Others

Global Neuroendocrine Tumors Treatment Market Size by Sites & CAGR (2026-2033)

• Market Overview
• Lung
• Pancreas
• Colon
• Small Intestine
• Rectum
• Stomach
• Others

Global Neuroendocrine Tumors Treatment Market Size by End Uses & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Others

Global Neuroendocrine Tumors Treatment Market Size & CAGR (2026-2033)

• North America (Tumor Types, Treatment Products, Sites, End Uses)
  • US
  • Canada
• Europe (Tumor Types, Treatment Products, Sites, End Uses)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Tumor Types, Treatment Products, Sites, End Uses)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Tumor Types, Treatment Products, Sites, End Uses)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Tumor Types, Treatment Products, Sites, End Uses)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hutchison MediPharma Limited (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AVEO Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharmova Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Advanced Accelerator Applications (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioSynthema Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations